Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review

Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival rate is estimated to be approximately 5–15%, considering all tumor stages. There is a significant unmet need for effective new tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anthony Vignone, Francesca Biancaniello, Marco Casadio, Ludovica Pesci, Vincenzo Cardinale, Lorenzo Ridola, Domenico Alvaro
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cholangiocarcinoma targeted therapy immunotherapy Medicine R
Acceso en línea:	https://doaj.org/article/82767877420544568ea0e262ab6c2d4e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82767877420544568ea0e262ab6c2d4e
record_format	dspace
spelling	oai:doaj.org-article:82767877420544568ea0e262ab6c2d4e2021-11-11T17:32:59ZEmerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review10.3390/jcm102149012077-0383https://doaj.org/article/82767877420544568ea0e262ab6c2d4e2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4901https://doaj.org/toc/2077-0383Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival rate is estimated to be approximately 5–15%, considering all tumor stages. There is a significant unmet need for effective new treatment approaches. The present review is provided with the aim of summarizing the current evidence and future perspectives concerning new therapeutic strategies for cholangiocarcinoma. The role of targeted therapies and immunotherapies is currently investigational in cholangiocarcinoma. These therapeutic options might improve survival outcomes, as shown by the promising results of several clinical trials illustrated in the present review. The co-presence of driver mutations and markers of susceptibility to immunotherapy may lead to rational combination strategies and clinical trial development. A better understanding of immunologically based therapeutic weapons is needed, which will lead to a form of a precision medicine strategy capable of alleviating the clinical aggressiveness and to improve the prognosis of cholangiocarcinoma.Anthony VignoneFrancesca BiancanielloMarco CasadioLudovica PesciVincenzo CardinaleLorenzo RidolaDomenico AlvaroMDPI AGarticlecholangiocarcinomatargeted therapyimmunotherapyMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4901, p 4901 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cholangiocarcinoma targeted therapy immunotherapy Medicine R
spellingShingle	cholangiocarcinoma targeted therapy immunotherapy Medicine R Anthony Vignone Francesca Biancaniello Marco Casadio Ludovica Pesci Vincenzo Cardinale Lorenzo Ridola Domenico Alvaro Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
description	Cholangiocarcinoma is a group of malignancies with poor prognosis. Treatments for the management of advanced-stage cholangiocarcinoma are limited, and the 5-year survival rate is estimated to be approximately 5–15%, considering all tumor stages. There is a significant unmet need for effective new treatment approaches. The present review is provided with the aim of summarizing the current evidence and future perspectives concerning new therapeutic strategies for cholangiocarcinoma. The role of targeted therapies and immunotherapies is currently investigational in cholangiocarcinoma. These therapeutic options might improve survival outcomes, as shown by the promising results of several clinical trials illustrated in the present review. The co-presence of driver mutations and markers of susceptibility to immunotherapy may lead to rational combination strategies and clinical trial development. A better understanding of immunologically based therapeutic weapons is needed, which will lead to a form of a precision medicine strategy capable of alleviating the clinical aggressiveness and to improve the prognosis of cholangiocarcinoma.
format	article
author	Anthony Vignone Francesca Biancaniello Marco Casadio Ludovica Pesci Vincenzo Cardinale Lorenzo Ridola Domenico Alvaro
author_facet	Anthony Vignone Francesca Biancaniello Marco Casadio Ludovica Pesci Vincenzo Cardinale Lorenzo Ridola Domenico Alvaro
author_sort	Anthony Vignone
title	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
title_short	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
title_full	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
title_fullStr	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
title_full_unstemmed	Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review
title_sort	emerging therapies for advanced cholangiocarcinoma: an updated literature review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/82767877420544568ea0e262ab6c2d4e
work_keys_str_mv	AT anthonyvignone emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT francescabiancaniello emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT marcocasadio emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT ludovicapesci emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT vincenzocardinale emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT lorenzoridola emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview AT domenicoalvaro emergingtherapiesforadvancedcholangiocarcinomaanupdatedliteraturereview
_version_	1718432072863842304

Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review

Ejemplares similares